Orexin-A vs Neuropeptide S
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Neuropeptide S (Neuropeptide S) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | Neuropeptide S |
|---|---|---|
| Category | Cognitive Enhancement | Cognitive Enhancement |
| Full Name | Hypocretin-1 (Orexin-A) | Neuropeptide S |
| Molecular Weight | 3562 Da | 2203 Da |
| Half-Life | Minutes to <1 hour | Minutes to <1 hour |
| Amino Acids | 33 | 20 |
| Typical Dose | Research-only; no validated human dose | Research-only; no validated human dose |
| Route | Intracerebroventricular/Intranasal | Intracerebroventricular/Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 28 |
| Research Status | Pre-clinical | Pre-clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.